MedPath

AS-2473662

Generic Name
AS-2473662
Clinical Trials
Related News

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Phase 1
Terminated
Conditions
Polymyalgia Rheumatica
Interventions
First Posted Date
2024-02-28
Last Posted Date
2025-05-16
Lead Sponsor
Sparrow Pharmaceuticals
Target Recruit Count
1
Registration Number
NCT06281236
Locations
🇩🇪

Klinische Forschung Hannover Mitte GmbH/Pratia, Hannover, Germany

🇩🇪

Emovis Gmbh, Berlin, Germany

🇩🇪

Klinikum der Universität München, München, Germany

and more 2 locations

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Phase 2
Completed
Conditions
Polymyalgia Rheumatica
Interventions
Drug: SPI-62 matched placebo
First Posted Date
2022-06-29
Last Posted Date
2025-05-11
Lead Sponsor
Sparrow Pharmaceuticals
Target Recruit Count
66
Registration Number
NCT05436652
Locations
🇵🇱

NovaReuma, Białystok, Poland

🇩🇪

Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin, Germany

🇩🇪

Internistische Praxisgemeinschaft Rheumatologie Nephrologie, Erlangen, Germany

and more 7 locations

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus in Obese
Obesity
Type2Diabetes
Interventions
Drug: Cortisone-d8
First Posted Date
2022-06-07
Last Posted Date
2024-04-22
Lead Sponsor
Sparrow Pharmaceuticals
Target Recruit Count
12
Registration Number
NCT05409027
Locations
🇺🇸

ProSciento, Chula Vista, California, United States

SPI-62 As a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Phase 2
Active, not recruiting
Conditions
Cortisol Excess
Cortisol Overproduction
Cushing's Syndrome I
Cushing Disease Due to Increased ACTH Secretion
Cortisol; Hypersecretion
Ectopic ACTH Secretion
Interventions
Drug: Placebo
First Posted Date
2022-04-01
Last Posted Date
2025-03-18
Lead Sponsor
Sparrow Pharmaceuticals
Target Recruit Count
26
Registration Number
NCT05307328
Locations
🇺🇸

Southwest General Healthcare Center, Fort Myers, Florida, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇧🇬

Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE), Sofia, Bulgaria

and more 9 locations

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Phase 2
Terminated
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
Drug: ASP3662 placebo
First Posted Date
2015-02-26
Last Posted Date
2019-03-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
115
Registration Number
NCT02372578
Locations
🇺🇸

Site US10013, Kettering, Ohio, United States

🇺🇸

Site US10039, Phoenix, Arizona, United States

🇺🇸

Site US10051, Boston, Massachusetts, United States

and more 34 locations

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

Phase 1
Completed
Conditions
Pharmacokinetics of ASP3662
Healthy Volunteers
Displacement of Radiotracer
Interventions
Other: [11C]AS2471907
Radiation: Positron Emission Tomography (PET)
First Posted Date
2014-07-18
Last Posted Date
2016-06-28
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
18
Registration Number
NCT02194491
Locations
🇺🇸

Site US10001, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy